Posted by Michael Wonder on 14 Feb 2018
Health Canada approves Ipsen's Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours
13 February 2018 - Somatuline Autogel is the first and only somatostatin analog approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome
Ipsen Biopharmaceuticals Canada today announced the Health Canada approval for Somatuline Autogel (lanreotide injection) 120 mg for the treatment of carcinoid syndrome; when used, Somatuline Autogel reduces the administrative frequency of short-acting somatostatin analog rescue therapy.
Somatuline Autogel is also approved for the treatment of enteropancreatic neuroendocrine tumours in adult patients with Grade 1 or a subset of Grade 2 (equivalent to Ki67<10%) unresectable, locally advanced or metastatic disease, to delay progression.
